ReviewResearch in pharmaceutical sciences2013
Metalloid compounds as drugs.
Review in Research in pharmaceutical sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- A Boronic Acid-Based Glutamine Analog Forms a Covalent Adduct with Kidney-Type Glutaminase and Suppresses Triple-Negative Breast Cancer Cell Proliferation.Biomedicines · 2026Article
- The role of silicon in drug discovery: a review.RSC medicinal chemistry · 2024Review
- Review
- Arsenic in medicine: past, present and future.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023Review
- Use of Microbial Consortia in Bioremediation of Metalloid Polluted Environments.Microorganisms · 2023Review
- Medicinal Hypervalent Tellurium Prodrugs Bearing Different Ligands: A Comparative Study of the Chemical Profiles of AS101 and Its Halido Replaced Analogues.International journal of molecular sciences · 2022Article
- Green synthesis of metalloid nanoparticles and its biological applications: A review.Frontiers in chemistry · 2022Review
- Organosilicon Compounds, SILA-409 and SILA-421, as Doxorubicin Resistance-Reversing Agents in Human Colon Cancer Cells.Molecules (Basel, Switzerland) · 2020Article
- State-of-Art Bio-Assay Systems and Electrochemical Approaches for Nanotoxicity Assessment.Frontiers in bioengineering and biotechnology · 2020Review
- Diphenyl Ditelluride: Redox-Modulating and Antiproliferative Properties.Oxidative medicine and cellular longevity · 2019Review
- Synthesis, Reactivity, Functionalization, and ADMET Properties of Silicon-Containing Nitrogen Heterocycles.Journal of the American Chemical Society · 2018Article
- Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.PLoS neglected tropical diseases · 2018Article
- Identification of Arsenic Direct-Binding Proteins in Acute Promyelocytic Leukaemia Cells.International journal of molecular sciences · 2015Article
- Corynebacterium diphtheriae putative tellurite-resistance protein (CDCE8392_0813) contributes to the intracellular survival in human epithelial cells and lethality of Caenorhabditis elegans.Memorias do Instituto Oswaldo Cruz · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The six elements commonly known as metalloids are boron, silicon, germanium, arsenic, antimony, and tellurium. Metalloid containing compounds have been used as antiprotozoal drugs. Boron-based drugs, the benzoxaboroles have been exploited as potential treatments for neglected tropical diseases. Arsenic has been used as a medicinal agent and arsphenamine was the main drug used to treat syphilis. Arsenic trioxide has been approved for the treatment of acute promyelocytic leukemia. Pentavalent antimonials have been the recommended drug for visceral leishmaniasis and cutaneous leishmaniasis. Tellurium (IV) compounds may have important roles in thiol redox biological activity in the human body, and ammonium trichloro (dioxoethylene-O, O'-)tellurate (AS101) may be a promising agent for the treatment of Parkinson's disease. Organosilicon compounds have been shown to be effective in vitro multidrug-resistance reverting agents.
Indexed as
Identifiers
24019824PMC3764666W2136707101What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.